BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, Anand AC, Bhangui P, Chawla YK, Datta Gupta S, Dixit VK, Duseja A, Kalra N, Kar P, Kulkarni SS, Kumar R, Kumar M, Madhavan R, Mohan Prasad VG, Mukund A, Nagral A, Panda D, Paul SB, Rao PN, Rela M, Sahu MK, Saraswat VA, Shah SR, Shalimar, Sharma P, Taneja S, Wadhawan M; INASL Task-Force on Hepatocellular Carcinoma. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol 2020;10:43-80. [PMID: 32025166 DOI: 10.1016/j.jceh.2019.09.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Kronenfeld JP, Ryon EL, Goldberg D, Lee RM, Yopp A, Wang A, Lee AY, Luu S, Hsu C, Silberfein E, Russell MC, Merchant NB, Goel N. Survival inequity in vulnerable populations with early-stage hepatocellular carcinoma: a United States safety-net collaborative analysis. HPB (Oxford) 2021;23:868-76. [PMID: 33487553 DOI: 10.1016/j.hpb.2020.11.1150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Huang Y, Ge W, Ding Y, Zhang L, Zhou J, Kong Y, Cui B, Gao B, Qian X, Wang W. The circular RNA circSLC7A11 functions as a mir-330-3p sponge to accelerate hepatocellular carcinoma progression by regulating cyclin-dependent kinase 1 expression. Cancer Cell Int 2021;21:636. [PMID: 34844614 DOI: 10.1186/s12935-021-02351-7] [Reference Citation Analysis]
3 Huang Y, Ge W, Zhou J, Gao B, Qian X, Wang W. The Role of Tumor Associated Macrophages in Hepatocellular Carcinoma. J Cancer 2021;12:1284-94. [PMID: 33531974 DOI: 10.7150/jca.51346] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
4 Anand AC, Acharya SK. New Developments in the Treatment of Hepatocellular Carcinoma: The Concept of Adjuvant and Neoadjuvant Chemotherapy. J Clin Exp Hepatol 2021;11:284-7. [PMID: 33994710 DOI: 10.1016/j.jceh.2021.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Mahajan A, Shetty A, Koteshwar P, Musunuri B, Shetty S, Bhat G. Complete Regression of Hepatocellular Carcinoma with Low Dose of Sorafenib. J Clin Exp Hepatol 2021;11:756-7. [PMID: 34866855 DOI: 10.1016/j.jceh.2021.06.012] [Reference Citation Analysis]
6 Acharya SK. Treatment for Hepatocellular Carcinoma in South Asia. J Clin Exp Hepatol 2021;11:641-5. [PMID: 34866841 DOI: 10.1016/j.jceh.2021.09.018] [Reference Citation Analysis]
7 Kumar A. Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma? J Hepatol 2020;73:467-8. [PMID: 32409208 DOI: 10.1016/j.jhep.2020.03.016] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Patel A, Subbanna I, Bhargavi V, Swamy S, Kallur KG, Patil S. Transarterial Radioembolization (TARE) with 131 Iodine-Lipiodol for Unresectable Primary Hepatocellular Carcinoma: Experience from a Tertiary Care Center in India. South Asian J Cancer 2021;10:81-6. [PMID: 34568220 DOI: 10.1055/s-0041-1731600] [Reference Citation Analysis]
9 Tohra S, Duseja A, Taneja S, Kalra N, Gorsi U, Behera A, Kaman L, Dahiya D, Sahu S, Sharma B, Singh V, Dhiman RK, Chawla Y. Experience With Changing Etiology and Nontransplant Curative Treatment Modalities for Hepatocellular Carcinoma in a Real-Life Setting-A Retrospective Descriptive Analysis. J Clin Exp Hepatol 2021;11:682-90. [PMID: 34866847 DOI: 10.1016/j.jceh.2021.02.002] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Chen H, Tao M, Li D, Han J, Cheng C, Ma Y, Wu Y, Shelat VG, Tustumi F, Satapathy SK, Kang KJ, Wang Q. An evaluation of the reporting quality in clinical practice guidelines for hepatocellular carcinoma using the RIGHT checklist. Ann Transl Med 2021;9:1004. [PMID: 34277804 DOI: 10.21037/atm-21-2611] [Reference Citation Analysis]
11 Zhong JH, Xing BC, Zhang WG, Chan AW, Chong CCN, Serenari M, Peng N, Huang T, Lu SD, Liang ZY, Huo RR, Wang YY, Cescon M, Liu TQ, Li L, Wu FX, Ma L, Ravaioli M, Neri J, Cucchetti A, Johnson PJ, Li LQ, Xiang BD. Repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a retrospective multicentre study. Br J Surg 2021:znab340. [PMID: 34643677 DOI: 10.1093/bjs/znab340] [Reference Citation Analysis]
12 Chen J, Xia C, Duan T, Cao L, Jiang H, Liu X, Zhang Z, Ye Z, Wu Z, Gao R, Shi Y, Song B. Macrotrabecular-massive hepatocellular carcinoma: imaging identification and prediction based on gadoxetic acid-enhanced magnetic resonance imaging. Eur Radiol 2021. [PMID: 33856520 DOI: 10.1007/s00330-021-07898-7] [Reference Citation Analysis]